This Viewpoint discusses the costs of emerging therapies for conditions prevalent in the US Baby Boomer population now entering old age and proposes principles to ensure the value and accessibility of new expensive drugs including cost-effectiveness (CE) assessments, price-benefit alignment, and incorporation of CE data into clinical practice guidelines.